Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 2:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 621 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Subutex Clear all
Completed Phase 3 Interventional Results available

Open-Label Treatment Extension Study

NCT02896296
View directory record Official record
Conditions
Opioid Use Disorder, Opioid-related Disorders
Interventions
RBP-6000
Drug
Lead sponsor
Indivior Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
29
States / cities
Hamilton, Alabama • Little Rock, Arkansas • Long Beach, California + 25 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2018 · Synced Oct 29, 2026, 2:48 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Intervention to Expand Opioid Use Disorder Treatment Pharmacotherapy Prescribers

NCT02926482
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
Prescriber Recruitment Bundle (PRB)
Behavioral
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
Not listed
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
3
States / cities
Tallahassee, Florida • Columbus, Ohio • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 13, 2024 · Synced Oct 29, 2026, 2:48 PM EDT
Completed Phase 2 Interventional Results available

Extended-Release Buprenorphine vs. Sublingual Buprenorphine for the Treatment of Opioid Use Disorder

NCT04352166
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
extended-release buprenorphine (BXR), sublingual buprenorphine (BSL)
Drug
Lead sponsor
Frances R Levin
Other
Eligibility
18 Years to 65 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 29, 2026, 2:48 PM EDT
Completed Phase 2 Interventional

Safety of the Buprenorphine Transdermal Delivery System in Subjects With Mod-to-Sev Pain Following Orthopedic Surgery.

NCT00315835
View directory record Official record
Conditions
Postoperative Pain
Interventions
Buprenorphine transdermal delivery system
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 1997
U.S. locations
1
States / cities
Plantation, Florida
Source: ClinicalTrials.gov public record
Updated Apr 19, 2006 · Synced Oct 29, 2026, 2:48 PM EDT
Completed Phase 1 Interventional

A Study to Assess the Drug-drug Interaction of BMS 663068 With Methadone and Also With Buprenorphine/Naloxone

NCT02666001
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
BMS-663068, Methadone, Buprenorphine and Norbuprenorphine
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
2
States / cities
Orlando, Florida • Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 9, 2017 · Synced Oct 29, 2026, 2:48 PM EDT
Recruiting Not applicable Interventional

Enhancing Addiction Treatment Through Psychoeducation

NCT07178158
View directory record Official record
Conditions
Substance Use Disorders
Interventions
Installing the Metacognium software app, Continue treatment as usual
Other
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 29, 2026, 2:48 PM EDT
Completed Phase 2 Interventional

Emergency Department-Initiated Buprenorphine Validation Network Trial

NCT04225598
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
CAM2038, Buprenorphine Sublingual Product
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
35
States / cities
Oakland, California • San Leandro, California • New Haven, Connecticut + 25 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2025 · Synced Oct 29, 2026, 2:48 PM EDT
Completed Phase 2 Interventional

Methadone/Buprenorphine Cross-Over Study - 4

NCT00000208
View directory record Official record
Conditions
Opioid-Related Disorders
Interventions
Buprenorphine
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
21 Years to 50 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1992
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 17, 2005 · Synced Oct 29, 2026, 2:48 PM EDT
Completed Phase 3 Interventional Results available

Neuroimaging Predictors of Relapse During Treatment for Opiate Dependence

NCT02696096
View directory record Official record
Conditions
Opioid Addiction
Interventions
FMRI, Suboxone
Other · Drug
Lead sponsor
Butler Hospital
Other
Eligibility
21 Years to 50 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Aug 17, 2022 · Synced Oct 29, 2026, 2:48 PM EDT
Completed Not applicable Interventional Results available

Duration of Analgesia After Popliteal Fossa Nerve Blockade: Effects of Dexamethasone and Buprenorphine

NCT01277159
View directory record Official record
Conditions
Patients Undergoing Ankle Surgery
Interventions
A. Control Nerve Block. IV Dexamethasone (4 mg)., B. Nerve Block with Dexamethasone (4 mg). IV saline., C. Control Nerve Block. IV Dexamethasone (4 mg). IV Buprenorphine (0.3 mg), D. Nerve Block with Buprenorphine (0.3 mg). IV Dexamethasone (4 mg)., E. Nerve Block with Dexamethasone (4 mg) / block Buprenorphine (0.3 mg).
Drug
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years to 75 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 14, 2022 · Synced Oct 29, 2026, 2:48 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Buprenorphine Induction and Naloxone Distribution Program-Combined With Warm Hand-Off Referral to Continued Treatment

NCT06087991
View directory record Official record
Conditions
Opioid Abuse
Interventions
Implementation of the BINDeR-Tx service model
Behavioral
Lead sponsor
Jerry Cochran
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 24, 2025 · Synced Oct 29, 2026, 2:48 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Buprenorphine/Raltegravir Pharmacokinetic Interaction Study

NCT00858962
View directory record Official record
Conditions
HIV Infection, HIV Infections
Interventions
Raltegravir
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 60 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 21, 2012 · Synced Oct 29, 2026, 2:48 PM EDT
Completed Phase 2 Interventional

Cariprazine for Comorbid Cocaine and Opioid Use Disorder

NCT05063201
View directory record Official record
Conditions
Opioid-use Disorder, Cocaine Use Disorder
Interventions
Cariprazine 1.5 MG, Placebo
Drug
Lead sponsor
Kyle Kampman
Other
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 23, 2026 · Synced Oct 29, 2026, 2:48 PM EDT
Completed Not applicable Interventional

Using Artificial Intelligence To Monitor Medication Adherence in Opioid Replacement Therapy

NCT02243670
View directory record Official record
Conditions
Opiate Addiction, Medication Non-adherence, Addiction, Opioid Dependence
Interventions
AiCure monitoring and intervention
Device
Lead sponsor
AiCure
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 12, 2017 · Synced Oct 29, 2026, 2:48 PM EDT
Completed Phase 1Phase 2 Interventional

CBT4CBT for Office Based Buprenorphine

NCT03580902
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
CBT4CBT-Buprenorphine, Buprenorphine/naloxone
Behavioral · Drug
Lead sponsor
CBT4CBT, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 4, 2023 · Synced Oct 29, 2026, 2:48 PM EDT
Withdrawn Phase 4 Interventional

Comparison of Buprenorphine/Naloxone With Naltrexone in Opioid Dependent Adolescents

NCT01015066
View directory record Official record
Conditions
Opiate Addiction
Interventions
Buprenorphine/naloxone, Naltrexone
Drug
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
16 Years to 25 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jun 10, 2014 · Synced Oct 29, 2026, 2:48 PM EDT
Completed Phase 1 Interventional

Pharmacokinetics, Safety, and Tolerability of Depot Buprenorphine at Three Different Molecular Weights in Treatment-Seeking Subjects With Opioid Use Disorder

NCT02559973
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
RBP-6000, SUBOXONE Sublingual Film
Drug
Lead sponsor
Indivior Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 31, 2017 · Synced Oct 29, 2026, 2:48 PM EDT
Withdrawn Not applicable Interventional

Use of Transcranial Magnetic Stimulation to Reduce Craving for Individuals With Opioid Use Disorder Taking Buprenorphine

NCT03653169
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
Transcranial Magnetic Stimulation
Device
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 14, 2022 · Synced Oct 29, 2026, 2:48 PM EDT
Active, not recruiting Not applicable Interventional

Counseling for Harm Reduction and Retention in Medication-assisted Treatment - Cherokee Nation

NCT05733442
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Treatment as usual (TAU), CHaRRM-CN
Other
Lead sponsor
Washington State University
Other
Eligibility
18 Years and older
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
Tahlequah, Oklahoma • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 29, 2026, 2:48 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Interscalene Block With Liposomal Bupivacaine vs. Interscalene Block With Bupivacaine and Adjuvants

NCT03845894
View directory record Official record
Conditions
Shoulder Arthroplasty
Interventions
Liposomal bupivacaine, Bupivacaine with adjuvants
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 13, 2023 · Synced Oct 29, 2026, 2:48 PM EDT
Completed Not applicable Interventional Results available

HEALing Communities Study

NCT04111939
View directory record Official record
Conditions
Opioid Use Disorder (OUD)
Interventions
Communities That HEAL, Wait-list control
Other
Lead sponsor
RTI International
Other
Eligibility
Not listed
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
4
States / cities
Lexington, Kentucky • Boston, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 29, 2026, 2:48 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Assessing Abuse Potential of Parenteral Buprenorphine/Naloxone in Non-Dependent Opioid Abusers

NCT00134875
View directory record Official record
Conditions
Opioid-Related Disorders
Interventions
Buprenorphine/naloxone
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 29, 2026, 2:48 PM EDT
Active, not recruiting Not applicable Interventional

Pain Care at Home to Amplify Function (Pain CHAMP)

NCT05333341
View directory record Official record
Conditions
Opioid Use Disorder, Opioid Misuse, Chronic Pain
Interventions
TCM, TCM plus COPES
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
259 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
3
States / cities
Little Rock, Arkansas • Aurora, Colorado • West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 30, 2026 · Synced Oct 29, 2026, 2:48 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Systems Analysis and Improvement to Optimize Opioid Use Disorder Care Quality and Continuity for Patients Exiting Jail

NCT06593353
View directory record Official record
Conditions
Opioid Use Disorder, Opioid Use Disorders
Interventions
Systems Analysis and Improvement Approach (SAIA)
Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 110 Years
Enrollment
4,186 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 29, 2026, 2:48 PM EDT